FLGT is recommended as the better investment choice due to its diversified growth platform, strategic acquisitions expanding pathology capabilities, AI/digital pathology investments improving efficiency, therapeutic pipeline with encouraging clinical findings, and valuation trading below its five-year median with room for upside.
The company is under investigation for potential federal securities law violations, reported revenue that fell short of updated guidance, and experienced sequential revenue decline in Q4, indicating operational and legal concerns that negatively impact investor confidence.
The company experienced a severe 38.1% stock price decline following disappointing 2026 guidance attributed to a major customer moving work in-house. Additionally, the company is under investigation for potential securities law violations, indicating serious operational and legal challenges.
Articles that tag FLGT but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
